Fatal hepatorenal failure and thrombocytopenia with SU5416, a vascular endothelial growth factor Flk-1 receptor inhibitor, in AIDS–Kaposi's sarcoma

Noy, Ariela; Roenn, Jamie Von; Politsmakher, Alex; Miles, Steven A.; Bachert, Claus

doi:10.1097/01.aids.0000254688.06831.28

Cited by 3 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many participants had previously received multiple KS treatments, but we did not note a pattern of response with respect to prior receipt of agents with anti-VEGF activity. Other studies of VEGF inhibitors in KS reported a 30% response rate for bevacizumab, 20% for sorafenib, and no better than SD for sunitunib [34, 39-41]. As such, this study highlights a persistent question in the search for improved therapies for KS and many soft tissue sarcomas (STS) which similarly over-express VEGF and its receptors [42].…”

Section: Discussionmentioning

confidence: 77%

Brief Report

Ignacio

lee

Rudek

et al. 2016

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

Vascular endothelial growth factor (VEGF) plays an important role in Kaposi’s sarcoma (KS). We administered PTC299, a post-transcriptional inhibitor of pathogenic VEGF, to persons with HIV-related KS. Seventeen participants received three different doses of PTC299. Adverse events typically observed with VEGF-inhibition were absent. Three participants had partial tumor responses and 11 had stable disease. There were no differences in exposure to PTC299 by antiretroviral regimen. Serum VEGF, but not KSHV DNA, decreased on treatment. Given redundancies in the VEGF feedback loop, future trials should consider combining PTC299 with agents that inhibit different pathways implicated in KS and KSHV proliferation.

show abstract

Section: Discussionmentioning

confidence: 77%

Brief Report

Ignacio

lee

Rudek

et al. 2016

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

show abstract

Kaposi's Sarcoma

Schwartz¹,

Facp²,

Faad³

2008

Skin Cancer

View full text Add to dashboard Cite

Pharmacological management of Kaposi's sarcoma

Sgadari¹,

Bacigalupo²,

Barillari³

et al. 2011

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Kaposi's sarcoma represents a paradigm of how the elucidation of disease pathogenesis can drive the development of molecularly targeted treatments. The multifactorial pathogenesis of KS has led to the evaluation of many experimental agents targeting one or more specific factors or pathways involved in the development or progression of the disease. Although targeted therapy so far represents investigational treatment, clinical evaluation of several of these agents is yielding promising results.

show abstract

Fatal hepatorenal failure and thrombocytopenia with SU5416, a vascular endothelial growth factor Flk-1 receptor inhibitor, in AIDS–Kaposi's sarcoma

Cited by 3 publications

References 8 publications

Brief Report

Brief Report

Kaposi's Sarcoma

Pharmacological management of Kaposi's sarcoma

Contact Info

Product

Resources

About